Advances in antiretroviral therapy (ART) have led to major decreases in HIV-related mortality. The long-acting injectable ART regimen of cabotegravir plus rilpivirine may help address barriers to adherence. In this article, Dr Ho discusses the importance of long-acting injectable ARTs in HIV treatment as well as topics in this area that need further investigation.
Special Collections
